Relay Therapeutics, Inc. financial data

Symbol
RLAY on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
399 Binney Street, 2 Nd Floor, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.88K % +32.3%
Debt-to-equity 13.8 % -19.7%
Return On Equity -43.7 % -15.4%
Return On Assets -38.4 % -18.9%
Operating Margin -1.03K % +96.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 134M shares +9.63%
Common Stock, Shares, Outstanding 133M shares +9.33%
Entity Public Float 1.5B USD -16.7%
Common Stock, Value, Issued 133K USD +9.02%
Weighted Average Number of Shares Outstanding, Basic 133M shares +9.16%
Weighted Average Number of Shares Outstanding, Diluted 111M shares +19.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 35.3M USD +2874%
Revenue from Contract with Customer, Excluding Assessed Tax 35.3M USD +2874%
General and Administrative Expense 75.2M USD +4.22%
Operating Income (Loss) -357M USD +2.48%
Net Income (Loss) Attributable to Parent -323M USD +6.27%
Earnings Per Share, Basic -2.51 USD/shares +13.4%
Earnings Per Share, Diluted -2.51 USD/shares +13.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 134M USD -8.07%
Accounts Receivable, after Allowance for Credit Loss, Current 211K USD -12.4%
Other Assets, Current 5.73M USD +69%
Assets, Current 704M USD -20.4%
Property, Plant and Equipment, Net 8.35M USD -28.9%
Operating Lease, Right-of-Use Asset 54.9M USD -9.83%
Assets 773M USD -19.7%
Accounts Payable, Current 11.2M USD -24.4%
Accrued Liabilities, Current 27.8M USD +3.21%
Contract with Customer, Liability, Current 83K USD -80%
Liabilities, Current 45M USD -37.1%
Operating Lease, Liability, Noncurrent 45.8M USD -10.4%
Liabilities 90.8M USD -40.2%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.34M USD +78%
Retained Earnings (Accumulated Deficit) -1.57B USD -25.8%
Stockholders' Equity Attributable to Parent 682M USD -15.8%
Liabilities and Equity 773M USD -19.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -50.3M USD +25%
Net Cash Provided by (Used in) Financing Activities 48.9M USD +3672%
Net Cash Provided by (Used in) Investing Activities 10.5M USD -86%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 133M shares +9.33%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.13M USD -3.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 137M USD -7.93%
Deferred Tax Assets, Valuation Allowance 300M USD +30.1%
Deferred Tax Assets, Gross 312M USD +25.8%
Depreciation 1.4M USD +16.5%
Payments to Acquire Property, Plant, and Equipment 1.78M USD -7.05%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -318M USD +6.06%
Property, Plant and Equipment, Gross 34.5M USD +14.9%
Operating Lease, Liability, Current 5.34M USD +15.7%
Deferred Tax Assets, Operating Loss Carryforwards 141M USD +18.2%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 2.26B USD +9.18%
Deferred Tax Assets, Net of Valuation Allowance 12.3M USD -30.3%
Share-based Payment Arrangement, Expense 95.1M USD +31.3%